We are live on ! Find out more
BLPH

Bellerophon Therapeutics

Delisted

BLPH was delisted on the 13th of October, 2023.

20 hedge funds and large institutions have $21.8M invested in Bellerophon Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more capital inflows, than outflows

Capital inflows: $2.14M | Capital outflows: $204K

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

54% more funds holding

Funds holding: 13 → 20 (+7)

0.56% more ownership

Funds ownership: 45.97% → 46.53% (+0.56%)

Holders
20
Holders Change
+7
Holders Change %
+53.85%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLPH Hedge Fund Activity: Q2 2017 in Review

20 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics (BLPH) for Q2 2017, worth a combined $21.8M — down 1.6% from $22.2M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new BLPH positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.35M. The largest seller was Goldman Sachs, exiting entirely with an estimated $125K sold.

  • 20 institutional investors held Bellerophon Therapeutics (BLPH) as of Q2 2017, up from 13 in Q1 2017.
  • Funds reported $21.8M of Bellerophon Therapeutics stock for Q2 2017, down 1.6% quarter-over-quarter.
  • 9 funds opened new Bellerophon Therapeutics positions in Q2 2017 and 2 closed out, a net change of +7 holders.
  • The largest Bellerophon Therapeutics buyer in Q2 2017 was Susquehanna International Group, an estimated $1.35M added.
  • The largest Bellerophon Therapeutics seller in Q2 2017 was Goldman Sachs, an estimated $125K sold.

Based on aggregated 13F filings for Q2 2017.